ANGOSTURA
12.2.2020 18:47:05 CET | Business Wire | Press release
The House of Angostura® has announced that world-renowned Trinidadian-born DJ, music producer and entrepreneur Christopher “Jillionaire” Leacock will add some star quality to the judging panel, and the celebration, at this year’s Angostura Global Cocktail Challenge. This biannual event, celebrates its 10th anniversary in 2020 and brings together bartenders worldwide for the chance to become the global champion. The Angostura® Global Cocktail Challenge Finals takes place on February 22 in Trinidad & Tobago, ahead of the greatest show on earth, Trinidad & Tobago Carnival.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200212005699/en/
Peter Sandström, CEO of Angostura® , comments: “The Angostura® Global Cocktail Challenge is the 10th anniversary of the competition and we wanted to do something special to mark the occasion. Partnering with Jillionaire made so much sense as his roots are inherently connected to the House of Angostura® . He has a strong understanding of Angostura’s place at the heart of Trinidad & Tobago culture, enormous passion for locally inspired music and drinks and his global following helps elevate the competition to showcase the extraordinary talents of our competitors to an international audience.”
The nine finalists of the Angostura® Global Cocktail Competition 2020 are: Shana Rajahram (Trinidad & Tobago), Marv Cunningham (The Bahamas), Chad Lawrence (Canada), Gustavo Costa (Brazil), Mike Jordhoy (France), Rohan Massie (Australia), Simon Dacey (United Kingdom), Vasile Dorofeev (Dubai) and Agung Satria (Vietnam).
Jillionaire, best known for his contributions to Major Lazer, an American electronic music group, brings a keen interest and understanding of the bar industry as part-owner of Clyde’s, a Trinidadian cocktail bar in Brooklyn, New York. He is well prepared to see the nine finalists compete, as they aim to wow the judges with cocktail prowess.
Jillionaire shares why he’s proud to join the Angostura® Global Cocktail Challenge judging panel: “I am a proud supporter of Trinidadian culture and have a personal interest in cocktail culture and one of our island’s biggest exporter - Angostura® . Angostura’s historic bitters are known the world over. I’m keen to shine a light on our celebrated rum and amaro which capture the flavours of Trinidad & Tobago. Whoever goes on to win the competition, will not only be representing Angostura® , they’ll be representing our island on the world stage, something I take seriously.”
Angostura Global Cocktail Competition Master of Ceremonies and Judging Panel
Jillionaire will join head judge and James Beard Award-winning beverage professional, Maxwell Britten. Other judges include Eryn Reece, Bar Director at The Wooly Public, Joe Schofield, co-owner of Schofield’s Bar, Angostura® Chief Brand Educator, Raymond Edwards, and the reigning Angostura® Global Cocktail Challenge Champion, Raymond Letoa. Hospitality industry veteran Ms Franky Marshall will serve as Master of Ceremonies. After the competition, Jillionaire will lead the after-party celebrations, performing a curated DJ set.
The winning bartender will receive the coveted title of “Angostura® Global Cocktail Challenge (AGCC) Champion,” a cash prize of US$10,000 and a two-year contract as the Angostura® Global Brand Ambassador for ANGOSTURA® aromatic bitters, ANGOSTURA® orange bitters, Angostura® Rums and Amaro di ANGOSTURA® , as well as the opportunity to revisit Angostura’s home in Trinidad & Tobago to serve as a judge at the next edition of the competition.
For more information about the competition, visit www.AngosturaGlobalCocktailChallenge.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200212005699/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom